Market Signal Briefing

Cryptocurrency XRP

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Arslan Butt

Crypto Writer

Arslan Butt

Part of the Team Since

Sep 2022

About Author

Arslan Butt is an experienced webinar speaker, market analyst, and content writer specializing in crypto, forex, and commodities. He provides expert insights, trading strategies, and in-depth analysis...

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

2 minutes ago

On February 2, 2026, XRP is trading between $1.59 and $1.61, continuing its recent decline as the overall crypto market faces pressure. In the past 24 hours, XRP fell about 3 to 4 percent, and over the last week, losses reached 12 to 16 percent.

This drop has brought XRP to its lowest point in almost nine months, about 19 percent below its January highs. Trading remains busy, with about $4 billion traded in one day. This shows that many traders are still active, even as prices fall.

For beginners, moves like this often show fear and uncertainty in the market, not a problem with the project itself.

Why XRP Is Falling: Bitcoin and the Bigger PictureA main reason XRP is having trouble is its strong link to Bitcoin. Currently, XRP moves in the same direction as Bitcoin about 87 percent of the time. So when Bitcoin falls, most other coins, including XRP, usually follow.

Investors are also responding to global economic worries. Recent changes in US Federal Reserve leadership have made people think interest rates could stay high for longer. When this happens, traders often lower their risk and move money out of volatile assets like crypto.

Simply put, XRP is not falling by itself. It is part of a larger market pullback.

XRP ETFs Show Buyers Stepping InEven though the price has dropped, there are some positive signs. On January 30, XRP exchange-traded funds (ETFs) had $16.79 million in net inflows, according to SoSoValue. This means more money went into these funds than came out, despite large withdrawals earlier in the week.

The biggest inflows came from:

21Shares’ TOXR ETF: $8.19 million Bitwise XRP ETF: $3.91 million Canary XRP ETF: $2.79 million Franklin’s XRPZ ETF: $1.90 million For new investors, this shows that some institutions view the recent drop as a chance to buy, not a reason to worry.

XRP Technical Analysis: Why $1.55 MattersLooking at the charts, XRP price prediction is bearish as XRP is still in a short-term downtrend, which means prices are mostly moving lower. On shorter time frames, XRP faces resistance near $1.65 to $1.68, while buyers are trying to hold support around $1.55.

A popular indicator called the RSI (Relative Strength Index) is close to 30, which often means selling pressure is easing. However, this does not yet confirm a rebound.

XRP Price Chart Source: TradingviewIf XRP falls below $1.55, the next level to watch is around $1.48. If it rises above $1.68, that would be the first sign of improving momentum, with a chance to recover toward $1.75 to $1.82.

Right now, XRP seems to be settling down instead of crashing. If selling keeps slowing and the overall market mood gets better, this period could help set up a steadier recovery in the future.

Bitcoin Hyper: The Next Evolution of BTC on Solana?Bitcoin Hyper ($HYPER) is bringing a new phase to the BTC ecosystem. While BTC remains the gold standard for security, Bitcoin Hyper adds what it always lacked: Solana-level speed. The result: lightning-fast, low-cost smart contracts, decentralized apps, and even meme coin creation, all secured by Bitcoin.

Audited by Consult, the project emphasizes trust and scalability as adoption builds. And momentum is already strong. The presale has surpassed $31.4 million, with tokens priced at just $0.013665 before the next increase.

As Bitcoin activity climbs and demand for efficient BTC-based apps rises, Bitcoin Hyper stands out as the bridge uniting two of crypto’s biggest ecosystems. If Bitcoin built the foundation, Bitcoin Hyper could make it fast, flexible, and fun again.

Click Here to Participate in the Presale

Popular market commentator Jim Cramer offered a cheeky take on Bitcoin's (CRYPTO: BTC) latest crash Sunday, urging Strategy Inc. (NASDAQ:MSTR) founder Michael Saylor to “jam up” the apex cryptocurrency. Cramer's Tongue-In-Cheek Remark In an X post, Cramer proposed that Saylor should wait until about 6:30 pm to observe the S&P futures, and then attempt to push Bitcoin's price up to $82,500 from $76,500.

Shalini Nagarajan

Crypto Reporter

Shalini Nagarajan

Part of the Team Since

Jan 2024

About Author

Shalini is a crypto reporter who provides in-depth reports on daily developments and regulatory shifts in the cryptocurrency sector.

Has Also Written

Last updated: 

1 hour ago

A fresh bout of turbulence hit Bitcoin and equities markets at the Asia open on Monday, after a historic wipeout in precious metals spilled into risk assets and left investors bracing for a packed week of earnings, central bank meetings and headline economic data.

In early trading, Bitcoin hovered around $75,000 after dipping below $76,000 in thin weekend conditions, revisiting levels last seen during the fallout from Donald Trump’s “Liberation Day” tariffs last year.

Asian share markets tracked Wall Street futures lower, as traders digested Friday’s metal shock and turned cautious ahead of a heavy calendar. MSCI’s broad Asia-Pacific index outside Japan fell 0.7%, and South Korea dropped 1.0%.

Japan stood apart. The Nikkei 225 gained 0.7% after opinion polls pointed to a landslide for Prime Minister Sanae Takaichi’s Liberal Democratic Party in next week’s lower house election, a result investors see as supportive of large-scale stimulus and a weaker yen.

Market snapshot Bitcoin: $75,549, down 4% Ether: $2,210, down 9.3% XRP: $1.56, down 6% Total crypto market cap: $2.62 trillion, down 4.3% The mood stayed skittish in commodities. Silver extended its rout and at one point fell another 5%, after Friday’s roughly 30% crash squeezed leveraged positions in what had become a crowded trade.

Gold also remained under pressure after a Friday slide that marked its steepest daily fall since 1983, while silver suffered its worst single-day loss on record.

Oil slipped almost 3% after Trump said over the weekend Iran was “seriously talking” with Washington, a comment that traders read as lowering the immediate risk of a US military strike. Iran stayed a key geopolitical swing factor for energy.

Markets Brace For Earnings And Central Bank DecisionsCurrency moves added another layer. The dollar stayed firm after Trump nominated Kevin Warsh as the next Federal Reserve chair, a pick markets viewed as potentially less friendly to rapid rate cuts, and more pointed about the Fed’s balance sheet.

Equity futures in Europe and the US edged lower, with S&P 500 futures down 0.2% and Nasdaq futures off 0.4% as investors positioned for results from Alphabet, Amazon and AMD, and for more scrutiny on AI spending after Microsoft drew a chilly reception.

That earnings focus lands alongside major policy meetings, including the Reserve Bank of Australia, European Central Bank and Bank of England, with markets pricing about a 75% chance the RBA lifts rates to 3.85% to tackle resurgent inflation.

Data due in Asia includes S&P Global manufacturing PMIs for Japan, South Korea and Taiwan, plus inflation prints for Indonesia and Pakistan, while Malaysia remains closed.

Bitcoin plunges below $85K, triggering $320M in liquidations as market volatility surges and traders scramble to manage leveraged positions.

Emir Abyazov2 min read

2 February 2026, 03:42 AM

Bitcoin price today plunged below the key $85,000 mark, shaking market sentiment and triggering a sharp wave of liquidations across crypto exchanges. The sudden drop pushed BTC down nearly 6% intraday, marking one of the steepest short-term corrections in recent weeks.

$320 Million in Liquidations Rock the MarketAccording to derivatives data, more than $320 million in crypto positions were liquidated over the past 24 hours, with Bitcoin accounting for the majority of wiped-out trades. Long positions made up over 80% of total liquidations, signaling that bullish traders were caught off guard by the rapid downturn.

Liquidations occur when leveraged traders fail to maintain margin requirements, forcing exchanges to automatically close positions. This creates a domino effect — as prices fall, more positions are liquidated, accelerating selling pressure and deepening volatility.

Why Did Bitcoin Fall Below $85K?Market analysts attribute the move to a mix of profit-taking near recent highs and broader macro uncertainty. After an extended rally, funding rates had climbed, signaling overcrowded long positions. The correction appears to have flushed excessive leverage from the system, resetting derivatives markets.

Interestingly, on-chain metrics show limited movement from long-term holders, suggesting the sell-off was largely driven by short-term traders. Historically, Bitcoin has experienced similar 10-15% pullbacks during bullish cycles before stabilizing.

Key support levels now sit around $82,000 and $80,000, with traders watching closely for either a rebound or further downside.

Despite the sharp dip, volatility remains a defining trait of the crypto market — and rapid corrections often reshape sentiment just as quickly as rallies build it.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Editor-in-Chief at Coinpaper, scaling data-driven editorial ops, SEO-led discovery, and audience-first storytelling across crypto, AI, and fintech.

Read more about

Bitcoin

Ethereum price today fell sharply beneath the crucial $2,200 support level, rattling traders as leveraged positions were crushed. The broader crypto market’s weakness, including Bitcoin pressure, added to the sell‑off, highlighting the fragility of sentiment around the second‑largest digital asset.

$180 Million in Liquidations Shake ETH TradersOver the past 24 hours, more than $180 million in Ethereum positions were liquidated, with long leveraged trades making up most of the losses. When ETH breaks key supports, forced liquidations can create cascading selling, pushing price action even lower and amplifying volatility.

Liquidations occur when traders using borrowed funds fail to maintain margin requirements, triggering automatic position closures by exchanges. This mechanism can intensify rapid downward moves like the recent slide under $2,200.

Analyst Sees Potential Drop Below $2,000Bloomberg analyst Mike McGlone warned that Ethereum could move below $2,000 if current market conditions persist, highlighting risks from macroeconomic uncertainty and elevated funding rates. His analysis suggests that while short-term traders face pressure, long-term holders may remain more stable.

On-chain data shows limited movement from long-term wallets, indicating the sell-off is largely driven by leveraged positions and short-term traders. Critical support levels now sit near $2,000 and $1,950.

In a related bearish outlook reported recently, analysts noted that if ETH loses major support zones, further declines below $2,000 could unfold, with prices possibly dipping into deeper demand areas that have historically been tested during sharp corrections.

What Traders Are Watching NowCritical support clusters now sit around $2,000 and down to $1,800, levels that analysts have flagged as possible next price floors if selling pressure continues. Traders are closely watching whether bulls can defend these zones or if further liquidation events will unfold.

Despite the current weakness, some market participants remain attentive for oversold bounces or technical relief rallies, typical in highly volatile crypto conditions.

XRP price extended losses and traded below $1.60. The price is now consolidating and might decline further if it remains below $1.50.

XRP price started a fresh decline below the $1.650 zone. The price is now trading below $1.60 and the 100-hourly Simple Moving Average. There is a key bearish trend line forming with resistance at $1.650 on the hourly chart of the XRP/USD pair (data source from Kraken). The pair could continue to move down if it stays below $1.650. XRP Price Dives 15% XRP price failed to stay above $1.80 and started a fresh decline, like Bitcoin and Ethereum. The price declined below $1.720 and $1.650 to enter a short-term bearish zone.

The price even spiked below $1.550. A low was formed at $1.50, and the price is now consolidating losses. There was a recovery wave above $1.550. The price even cleared the 23.6% Fib retracement level of the downward move from the $1.938 swing high to the $1.50 low.

The price is now trading below $1.60 and the 100-hourly Simple Moving Average. If there is a fresh upward move, the price might face resistance near the $1.60 level. The first major resistance is near the $1.650 level. There is also a key bearish trend line forming with resistance at $1.650 on the hourly chart of the XRP/USD pair.

Source: XRPUSD on TradingView.com A close above $1.650 could send the price to $1.720 or the 50% Fib retracement level of the downward move from the $1.938 swing high to the $1.50 low. The next hurdle sits at $1.770. A clear move above the $1.770 resistance might send the price toward the $1.80 resistance. Any more gains might send the price toward the $1.8350 resistance. The next major hurdle for the bulls might be near $1.90.

Another Decline? If XRP fails to clear the $1.60 resistance zone, it could start a fresh decline. Initial support on the downside is near the $1.540 level. The next major support is near the $1.5150 level.

If there is a downside break and a close below the $1.5150 level, the price might continue to decline toward $1.50. The next major support sits near the $1.4650 zone, below which the price could continue lower toward $1.420.

Technical Indicators

Hourly MACD – The MACD for XRP/USD is now gaining pace in the bearish zone.

Hourly RSI (Relative Strength Index) – The RSI for XRP/USD is now below the 50 level.

Major Support Levels – $1.540 and $1.50.

Major Resistance Levels – $1.60 and $1.650.

Contrary to a common assumption, not all utility stocks are the same.

Artificial intelligence (AI) is still the biggest and best investment opportunity of an entire generation. But are investors looking right past the best way to play it?

Maybe. As it turns out, the industry's most underappreciated bottleneck isn't a lack of computing power, or for that matter, a lack of AI data centers. It's a lack of the massive amount of electricity needed to power the business. Goldman Sachs predicts that data centers' worldwide demand for electricity is set to grow by 165% between 2023 and 2030, mostly led by the ongoing proliferation of artificial intelligence.

There are several ways to supply this energy, with some operators even establishing their own on-premise power production facilities. Utilities companies remain best positioned to meet this growing need, though, and likely will be for the foreseeable future. They'll also see a great deal of unexpected growth, rewarding shareholders as a result.

And one of these utility names is arguably better positioned to plug into this growth than any of its peers. That's Constellation Energy (CEG 2.35%).

Image source: Getty Images.

Constellation is unique If the name rings a bell, it may be because Constellation was the company that announced in September 2024 it intended to restart one of the nuclear power reactors at Pennsylvania's infamous Three Mile Island, after agreeing to supply electricity to a nearby AI data center owned and operated by technology giant Microsoft.

This is only a microcosm of the much bigger dynamic in place at this time, though, as well as Constellation Energy's ability to quickly increase production of electricity that the world is now demanding. With 21 nuclear reactors at 12 different sites accounting for 86% of its output, this company is the nation's single-biggest producer of carbon-free electricity. In fact, this outfit has more nuclear power production potential than the rest of the United States' nuclear producers combined.

Perhaps more important to interested investors, however, is the fact that this nuclear-rich mix means Constellation's got room to increase output from its existing and operational nuclear reactors quickly. That's why its usually slow-growing top line is expected to experience accelerated growth this year and next, and continue accelerating from there once Three Mile Island is brought back online, and as other production projects are completed and brought online.

Data sources: StockAnalysis.com, Simply Wall St. Chart by author.

Right place, right time, right product Nuclear power isn't the only option to supply AI-focused data centers with the power they need, of course. Electricity is electricity regardless of how it's produced.

Nuclear power solves the enormous problem here and now, though, and does so cost-effectively. That's why Goldman Sachs adds that global nuclear power production is set to grow more than 50% by 2040. Meanwhile, boosted by executive orders issued by President Donald Trump, the World Nuclear Association predicts the United States' nuclear power production capacity could quadruple by 2050. Given that Constellation Energy is already a well-proven player in this space, it's difficult to see how it wouldn't be one of the biggest beneficiaries of this evolution of the energy industry.

Today's Change

(

-2.35

%) $

-6.77

Current Price

$

280.68

The stock's recent setback stemming from the federal government's threats of capping electricity rates following its third quarter is more near-term noise than long-term warning, creating a nice buying opportunity here.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Constellation Energy, Goldman Sachs Group, and Microsoft. The Motley Fool has a disclosure policy.

There is a good reason why Micron's stock is cheap.

Finding cheap stocks with huge growth potential is a potent combination. This combines value investing with growth investing, and if done correctly, can yield incredible investment returns.

One area that has gotten a lot of attention over the past few years is artificial intelligence (AI), so it seems odd to find a value stock hiding in this area. However, Micron (MU 4.87%) appears to be that way.

Wall Street expects huge growth this year, yet the stock trades for a relatively cheap price tag. So is this a genius buy? Or is there a catch?

Image source: Getty Images.

Micron's stock is cheap for a reason Micron makes memory chips, which are distinctly different from logic chips such as those produced by Taiwan Semiconductor Manufacturing. The primary difference between memory and logic chips is that there isn't really any differentiating technology between memory chips. This area has become commoditized, which means the companies in the space have relatively little pricing power.

Today's Change

(

-4.87

%) $

-21.23

Current Price

$

414.56

However, if demand outstrips supply, then prices can skyrocket, and that's exactly what's happening.

If you haven't checked on RAM prices for laptops or computers recently, do yourself a favor and research them. Prices have spiked because memory chips are being completely consumed by the massive demand caused by the data centers being built to power generative AI. As a result, companies like Micron can increase their prices to account for the huge supply imbalance.

This is the core reason why Micron's earnings are expected to explode throughout the year. Micron's fiscal year 2026 ends in August, and Wall Street analysts expect Micron's earnings per share (EPS) to increase from $8.29 in FY 2025 to $33.31 in FY 2026. Beyond that, they expect further growth to $42.79 in FY 2027. That's huge growth powered by insatiable AI demand, and it may be several years before memory companies have built enough capacity to meet demand.

But that's the major problem with Micron. Memory demand is incredibly cyclical, and it could crash shortly after Micron and its peers have built enough production capacity to meet demand. This will reduce memory chip prices and cause the stock to slump. The market is well aware of this, which is why the company's stock trades for a dirt cheap 13 times forward earnings.

MU PE Ratio (Forward) data by YCharts

The primary question is: How long will AI demand last? Many estimates expect the buildout to occur through at least 2030, which gives Micron stock about five years to benefit from soaring memory prices. This factor could make Micron stock a great buy now, but you'll have to pay attention to the right time to sell.

I prefer my investments to be a bit steadier, which is why I don't own Micron stock. However, I still think there's a great investment opportunity here, and savvy investors can make a great return by investing in Micron stock.

Keithen Drury has positions in Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Micron Technology and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.

Rising free cash flow, a 4% dividend, and a new $10 billion share buyback program have investors hitting the buy button.

Shares of AT&T (T +4.30%) jumped more than 10% this past week, according to data from S&P Global Market Intelligence.

The wireless carrier delivered an impressive quarterly financial report and issued a bullish long-term growth forecast.

Image source: AT&T.

AT&T is back to its winning ways A focus on bundled offerings is helping AT&T attract more customers. The communications leader won 421,000 postpaid phone and 283,000 fiber subscribers in the fourth quarter.

During a conference call with analysts, CEO John Stankey said AT&T saw an upturn in the portion of its fiber customers that also subscribed to its wireless services.

"Our fiber convergence rate climbed 200 basis points year over year to 42%, which is our fastest annual increase since we began tracking this metric," Stankey said. "This is further evidence that where we have fiber, we win with fiber and 5G."

Today's Change

(

4.30

%) $

1.08

Current Price

$

26.21

Moreover, AT&T's postpaid churn rate -- an important metric of account cancellations -- came in at less than 1%. Investors were happy to see that the wireless giant was also doing an admirable job of retaining its existing customers, despite the promotional activity of rivals like Verizon and T-Mobile.

More cash for shareowners In all, AT&T's convergence-based strategy helped it generate $16.6 billion in free cash in 2024. The telecom expects that figure to grow to more than $21 billion by 2028.

AT&T intends to pass much of that cash on to shareholders. Its stock currently sports a 4.2% dividend yield. The company's board of directors also approved a new $10 billion stock buyback program.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends T-Mobile US and Verizon Communications. The Motley Fool has a disclosure policy.

Alliance to Enhance Shonan Beauty Clinic Brand Recognition in China and Support Growth in Inbound Medical Demand to Japan

, /PRNewswire/ -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced that Medical Corporation Nasukai, a Japan-based medical corporation supported by SBC Medical and the operator of Shonan Beauty Clinic, has entered into a strategic business alliance with Daibi Medical Aesthetics, a medical aesthetic clinic based in Shanghai, China. The alliance aims to enhance the quality of services at Daibi Medical Aesthetics by sharing Nasukai's clinical expertise, operational know-how, and customer-centered practices cultivated by its long-standing experience in aesthetic medicine. The collaboration also seeks to strengthen recognition in China of the Shonan Beauty Clinic brand's safety standards and advanced medical technologies.

Commemorative photo following the signing ceremony held at Daibi Medical Aesthetics These efforts aim to deepen SBC Medical's understanding of China's medical environment and customer needs, while supporting increased inbound customer visits to Shonan Beauty Clinic in Japan and exploring long-term revenue opportunities associated with growing cross-border medical demand.

Established in 2021, Daibi Medical Aesthetics subsequently opened its clinic in 2022 in Shanghai's North Bund area. The clinic operates approximately 2,200 square meters of floor space and provides community-based medical aesthetic services. Under the alliance, physicians affiliated with Nasukai will work within Daibi Medical Aesthetics' clinical framework to share knowledge and expertise related to medical safety, clinic operations, and consultation practices. The two parties will also explore opportunities to promote mutual understanding and professional exchange in the field of aesthetic medicine between Japan and China, with specific initiatives being considered in phases.

The alliance comes amid growing global interest in medical tourism, defined as international travel for the purpose of receiving medical services. According to Fortune Business Insights, the global medical tourism market is projected to grow at a compound annual growth rate (CAGR) of 23.0% from 2024 to 2032, reaching approximately USD 62.18 billion by 2032.

As global interest in medical tourism continues to rise, Japanese aesthetic medicine has gained strong recognition, particularly across Asia, for its advanced medical technologies, safety standards, and attentive consultation practices. Reflecting this trend, inbound customer visits to Shonan Beauty Clinic have increased steadily, nearly tripling from approximately 600 customers in early 2024 to around 1,700 customers by the end of 2025.To support this growing demand, Shonan Beauty Clinic has enhanced its inbound medical infrastructure through initiatives such as the development of Chinese-language translation tools and the renewal of its Chinese and English language official websites, providing overseas customers with clear and reliable medical information and a supportive care environment.

Shonan Beauty Clinic (Chinese): https://cn.sbc-beauty.com/
Shonan Beauty Clinic (English): https://en.sbc-beauty.com/

This alliance is expected to further support these efforts by enabling deeper insight into medical practices and customer expectations in China, contributing to a more seamless and consistent customer experience from pre-visit information to post-treatment follow-up, while also supporting improvements in the quality and reliability of aesthetic medical services at the local level.

Through its consulting and management support for medical institutions including Shonan Beauty Clinic, SBC Medical remains committed to building constructive partnerships with local stakeholders, fostering sustainable international medical exchange through medical tourism, and delivering customer-centered medical care that transcends national and regional boundaries.

About Daibi Medical Aesthetics
Location: Room 3301, No. 1158 Dongdaming Road, Hongkou District, Shanghai, China
CEO: Haibo Yu
Business: Provision of medical aesthetic services

About Nasukai
Location: 2F Maruito Ginza Building, 1-3-9 Ginza, Chuo-ku, Tokyo, Japan
Chairman: Keisuke Takeda
Business: Comprehensive medical services spanning specialized medicine, aesthetic medicine, insured medical care, and elective treatments

About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com/
For more insights and updates from SBC Holdings, follow us on LinkedIn

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.

Contacts
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of IR Department E-mail: [email protected]
Akiko Wakiyama / Head of Public Relations: E-mail: [email protected]

ICR LLC (US Time)
Bill Zima / Managing Partner E-mail: [email protected]

SOURCE SBC Medical Group Holdings Incorporated

HomeIndustriesSoftwareTech StocksTech StocksAfter issuing an $18 billion bond offering last fall, Oracle intends to tap the debt and equity markets anew in 2026Published: Feb. 1, 2026 at 9:04 p.m. ET

To finance its artificial-intelligence ambitions, Oracle is looking to raise more money, which could further stoke Wall Street’s fears about the level of financing underpinning the AI boom.

The company announced on Sunday that it intends to raise $45 billion to $50 billion in “gross cash proceeds” this year, split approximately between debt and equity issuance.

It's going to be a tale of two halves for the company this year.

UPS (UPS +0.26%) management surprised the market with its fourth-quarter earnings and guidance last week. The most salient update was free-cash-flow (FCF) guidance for $6.5 billion in 2026, up from an adjusted figure of $5.5 billion in 2025. That will be more than enough to cover its planned $5.4 billion in dividends, which currently yield 6.1%.

As such, the stock appears highly attractive to investors seeking passive income. Still, is it enough to make the stock a buy?

Image source: Getty Images.

UPS guidance The guidance for FCF of $6.5 billion in 2026 is significantly above the Wall Street analyst consensus of $5.3 billion going into the earnings report. To be fair, it's something CFO Brian Dykes said would happen back in October, when discussing FCF in the context of covering the dividend: "We've got a dividend of around $5.4 billion to $5.5 billion, and we expect it [free cash flow] to be above that in the very near future."

Today's Change

(

0.26

%) $

0.28

Current Price

$

106.27

What UPS has to do to hit guidance The case for investing in UPS centers on its plan to focus on more profitable deliveries, such as those for small and medium-sized businesses (SMBs) and healthcare operations. By moving away from lower-margin deliveries, such as those from Amazon, UPS aims to become a more profitable, cash-generating company.

Those adjustments involve investing in automation and smart facilities to improve productivity (allowing for 93 building closures in 2025 with plans for another 24 in the first half of 2026). In addition, CEO Carol Tomé said UPS had 127 buildings automated at the end of 2025 and planned to add another 24 in 2026, resulting in 68% of U.S. volume processed through automated facilities at the end of 2026, up from 66.5% at the end of 2025. She also noted cost per piece (CPP) was 28% lower in automated buildings.

All these changes are expected to result in U.S. cost per piec normalizing from an adjusted rate of 7.2% in 2025 to "kind of normal inflation level," according to Dykes, on the earnings call. At the same time, management expects revenue per piece (RPP) to grow by a mid-single-digit percentage in 2026.

As such, management expects to end 2026 with revenue per piece above cost per piece as part of a year of inflection characterized by declining revenue (as Amazon deliveries continue to decline) and operating profit margins in the first half. This is expected to lead to a reversal of fortune in the second half as non-Amazon SMB deliveries and enterprise deliveries grow at a mid-single-digit rate, resulting in revenue and margin expansion.

UPS should exit 2026 in good shape The result is forecast to be slightly better revenue growth and a similar adjusted operating profit.

Metric 

2024

2025

2026 Estimate

Revenue

$91.1 billion

$88.7 billion

$89.7 billion

Adjusted operating profit margin

9.8%

9.8%

9.6%

Adjusted operating profit

$8.9 billion

$8.7 billion

$8.6 billion

Data source: UPS presentations.

Although the 2026 headline guidance may not stand out, the main takeaway is that UPS will reach a turning point in 2026. By the end of the year, profit margins should expand, revenue per piece will grow faster than cost per piece, and the company will generate higher-quality revenue thanks to less reliance on Amazon and greater growth in healthcare and SMB revenue.

In addition to the $3.5 billion in savings generated in 2025, management plans another $3 billion in cost savings as it lays off 30,000 workers and closes buildings. Meanwhile, the FCF estimate of $6.5 billion is supported by an intended reduction in capital spending to $3 billion in 2026 from $3.7 billion in 2025.

Image source: Getty Images.

Is UPS stock a buy? Based on management's outlook, UPS stock is attractive and will suit investors seeking passive income. That said, the tale of two halves means investors will have to be patient to see the full benefits of management's actions in the numbers. Furthermore, investors are entitled to ask whether the capital spending cut and the $5.4 billion in dividends are holding back investment in automation and technology (further improving productivity) or investments to fuel revenue growth in chosen end markets.

UPS looks good as a cautious buy for investors right now, but there's a lot of work to do before it hits the forecast numbers that make its stock look attractive.

HomeStock IdeasLong IdeasHealthcare 

SummaryProtalix Bio Therapeutics (PLX) received a positive CHMP opinion for Elfabrio’s every-four-weeks dosing in stable adult Fabry patients, pending EC approval by March.PLX’s Elfabrio could halve infusion frequency, improving patient quality of life and potentially strengthening its competitive position in the Fabry market.Elfabrio drove over half of PLX’s FY24 product revenue, with sales rising and a potential $25 million milestone tied to EU approval.PLX trades at a modest 2.7x EV/sales, but investor sentiment remains highly sensitive to Elfabrio uptake and regulatory milestones. Maskot/DigitalVision via Getty Images

Thesis As you know, Protalix Bio Therapeutics (PLX) has just announced some news that should serve as a very positive regulatory and clinical milestone for their Fabry disease treatment in Europe. You see, the EMA’s Committee for Medicinal Products for

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Ride hailing was only the start as the company adapts to an AI-driven world.

Shares of Uber Technologies (UBER 2.02%) were on a roll over the past year, hitting a 52-week high of $101.99 on Sept. 22, 2025. But after the ride-hailing giant released third quarter 2025 earnings on Nov. 4, its stock price began to slide.

A contributing factor was a massive rise in Uber's capital expenditures. In the third quarter, capex totaled $98 million, more than double the $42 million spent in the prior year. This increase was due to the company's investments in strategic areas, including autonomous vehicles (AVs).

The drop in share price is a boon for investors, creating a buy opportunity. That's because Uber is a great stock to own for many reasons. Here are three of them.

Image source: Getty Images.

Uber's AV strategy Although Wall Street frowned on Uber's capex jump, the increase illustrates the company is making investments to secure its long-term future. As CEO Dara Khosrowshahi explained, "Great technology companies deliver today while building for tomorrow."

That future involves autonomous automobiles. The company previously attempted to implement a fleet of AVs, but ultimately sold that division in 2020, choosing instead to focus on a partnership strategy.

In the ensuing years, Uber spun up numerous deals with AV companies around the globe. These include Alphabet-owned Waymo, U.K.-based Wayve, and Chinese tech giant Baidu to deploy thousands of AVs around the world on Uber's platform.

This strategy is smart. Uber doesn't incur the costs of building self-driving cars, but still plays a key role for its partners, enabling it to ride the tailwind of a growing industry in a capital-efficient manner.

The company's self-driving car approach has grown more ambitious. Uber is partnering with artificial intelligence (AI) semiconductor titan Nvidia to combine Nvidia's autonomous vehicle technology with its platform.

Together, they will offer a scalable global ride-hailing ecosystem, bringing together robot and human drivers. Businesses such as Stellantis and Lucid are leveraging Nvidia's AV tech, and as these other companies deliver robotaxis to market, they can seamlessly add their fleets to Uber's marketplace. In fact, Stellantis is already working with Uber.

Today's Change

(

-2.02

%) $

-1.65

Current Price

$

80.05

Uber's burgeoning business Uber has already extended its ride-hailing model into delivery services. It's now working to expand into a new field of work brought on by the arrival of artificial intelligence.

The company is calling this area Uber AI Solutions. This division will focus on providing services to help businesses build high-quality AI models. Just as Uber's platform matches passengers to drivers, its new AI-focused work will connect companies constructing AI with professionals to perform tasks such as testing AI models and validating AI's language translations.

Uber's expansion into other types of work is building on its successful platform model, which saw ride-hailing revenue grow 20% year over year to $7.7 billion and delivery sales jump 29% year over year to $4.5 billion in Q3 2025. This contributed to overall Q3 revenue growth of 20% year over year to $13.5 billion.

Uber's outstanding financials The company's rising revenue is just the start of its robust financials, contributing to Q3 2025 net income attributable to Uber of $6.6 billion, up from $2.6 billion in 2024. Consequently, Q3 diluted earnings per share (EPS) soared to $3.11 compared to $1.20 in the prior year.

That's just the start, according to Uber CFO Prashanth Mahendra-Rajah. He stated, "Understand that we are committed to annual profit expansion -- year-over-year profit expansion for as far into the future as we can see."

His words are not an idle boast. Uber's diluted EPS has been rising steadily for the last few years.

UBER EPS Diluted (TTM) data by YCharts.

This is one way the company has delivered outstanding growth in shareholder value. Uber also knocked it out of the ballpark in terms of free cash flow per share, with the metric increasing over the past several years.

This indicates the company is generating more cash than it needs for operations and capital expenditures, signaling robust financial health and giving Uber financial flexibility for initiatives such as stock buybacks.

UBER Free Cash Flow Per Share data by YCharts.

Contrasting these excellent financial results against Uber's share price shows its valuation has reached an attractive level. This can be seen in the price-to-earnings ratio.

The chart shows Uber's earnings multiple in 2026 is lower than back in April, when the Trump administration's tariff policies caused the stock market to plunge, suggesting Uber shares are a great value now.

UBER PE Ratio data by YCharts.

The fact that Uber management is thinking beyond ride-hailing and investing accordingly, hence its growth in capex, demonstrates its desire to become a bigger business than it is today. It's taken existing strengths in transportation data and married it with the AV industry. Next, it's expanding into the heart of AI technology with Uber AI Solutions.

Given Uber's exciting future and Wall Street's current shortsightedness, now is a great opportunity to grab Uber shares at a compelling valuation.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Ardent between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 1, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardent Health, Inc. ("Ardent" or the "Company") (NYSE: ARDT) and reminds investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose information regarding Ardent Health's accounts receivable. During the Class Period, Defendants publicly reported the Company's accounts receivable on a quarterly basis. In addition, Defendants represented that the Company maintained professional malpractice liability insurance in amounts "sufficient to cover claims arising out of its operations."

On November 12, 2025, Ardent announced its financial results for the third quarter of 2025. The Company revealed a $43 million reduction in its revenue due to accounting changes, and a $54 million increase in professional liability reserves.

On this news, Ardent's stock price fell $4.75 per share, or 33.81%, to close at $9.30 per share on November 13, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Ardent Health class action, go to www.faruqilaw.com/ARDT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282198

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Apple just turned in one of its best quarters in several years.

While Apple (AAPL +0.47%) saw its fiscal first-quarter revenue soar, the stock barely budged after the company reported its results. The stock is up less than 10% over the past year and down about 5% on the year, as of this writing.

With iPhone sales suddenly accelerating, is now a good time to buy the stock?

Today's Change

(

0.47

%) $

1.20

Current Price

$

259.48

iPhone momentum continues After a couple of years of sluggish sales, Apple's recent iPhone momentum continued in its fiscal Q1, with the company posting its strongest revenue growth since shortly after the pandemic in 2021.

The iPhone is Apple's biggest source of revenue, making up nearly 60% of its sales in the quarter. Sales soared for the smartphone in fiscal Q1 2026, climbing 23% to $85.27 billion and coming in well ahead of analyst expectations for $78.65 billion in iPhone revenue, as compiled by LSEG. CEO Tim Cook called demand for the iPhone "staggering."

Sales of Apple's other products were mixed. iPad sales rose 6% to $8.6 billion, with half of its customers new to the product. However, Mac sales fell 7% year over year to $8.4 billion, while wearable revenue slipped 2% to $11.5 billion.

Total product segment sales increased by 16% to $113.7 billion. China was an area of strength, with revenue climbing 38%. Apple's services segment -- which consists of its App Store, iCloud storage, Google Search revenue sharing, Apple Pay, Apple TV, and more -- meanwhile, saw revenue jump by 14% to $30 billion.

Product gross margin rose by 450 basis points sequentially to 40.7%, while service margin increased by 120 basis points sequentially to 76.5%. Overall gross margin was 48.2%. Despite rising memory prices, Apple expects to keep gross margin in line in Q2, with it projected to be between 48% and 49%.

Overall, Apple's revenue climbed by 16% to $143.76 billion, while its earnings per share (EPS) jumped 19% to $2.84. That topped the analyst consensus estimates for EPS of $2.67 on sales of $138.48 billion.

For fiscal Q2 2026, Apple expects its revenue to grow by 13% to 16% year over year, with services revenue rising at a comparable level to fiscal Q1.

Image source: Getty Images.

Is it time to buy Apple stock? Apple has remedied its biggest areas of weakness -- sluggish iPhone sales and a weak China -- and it is seeing some of its best growth in several years. However, the stock has not moved much on this improvement.

This can largely be attributed to its valuation. The stock climbed through a period of pretty lackluster results, pushing up its valuation multiple. Today, it trades at a forward price-to-earnings (P/E) ratio of around 31 based on analysts' estimates for fiscal 2026 (which will end in September) and 28 times fiscal 2027 estimates. That's more expensive than many of the "Magnificent Seven" stocks.

As such, the stock looks appropriately priced at this point. This could limit some of its upside, despite its strong operational momentum.

HomeDividends AnalysisDividend Quick Picks

SummaryMy Top 15 dividend growth stocks for February 2026 offer a 1.52% yield, 15.48% five-year dividend growth, and are about 27% undervalued.The Quality tilt outperformed Original and Value variants in January 2026, though all trailed VIG and SPY benchmarks.Since inception, the watch list has a 10.12% CAGR, below the 12% target, but 62% of selections delivered positive gains.The list is designed as a quantitative starting point to identify high-quality, attractively valued stocks for further research. Phimprapha Kitaiamphaisan/iStock via Getty Images

Quality Stocks Despite some elevated volatility in the final week of January the broad U.S. market started the year out in the green. The SPDR® S&P 500® ETF (SPY) posted a gain of

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZTS, INTU, DPZ, MSCI, BMI, MSFT, MA, ADP, ACN, V, PAYX, MRSH, ROL, NKE, SBAC, WST, CDW, FDS, MPWR, LLY, NVDA, AVGO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bitcoin's Fall, Why Now Is The Time For A Contrarian-Long IBIT Play

Strategy founder Michael Saylor has hinted his firm added to its Bitcoin holdings after the cryptocurrency slid more than 13% over the weekend, briefly pushing the company’s large BTC position into the red. 

“More Orange,” the Strategy executive chairman posted to X on Sunday alongside a chart showing his firm’s $55 billion worth of Bitcoin purchases since August 2020. Saylor often posts the chart as a signal that his company has bought or plans to buy Bitcoin.

Source: Michael SaylorIt would mark Strategy’s fifth Bitcoin (BTC) purchase this year, with its largest coming on Jan. 20, when it bought 22,305 Bitcoin. Strategy is by far the largest Bitcoin treasury company, with over 712,647 Bitcoin under management

Strategy’s early Bitcoin purchases, along with Bitcoin's rising price, have meant that over the last five years, the company has mostly been profitable from its Bitcoin holdings.

However, Bitcoin’s fall from $87,970 to $75,892 over the weekend briefly pushed it below Strategy’s cost basis of $76,040, before Bitcoin later rebounded to $76,765.

The crash came after US President Donald Trump nominated former Federal Reserve governor Kevin Warsh to replace Jerome Powell as the central bank’s chair on Friday.

While Warsh has spoken favorably of Bitcoin, he is widely seen as a more hawkish Fed chair pick who would push for fiscal restraint, lower inflation, and an exit from quantitative easing.

Gold and silver also fell significantly on Trump’s announcement — dropping by double digits after a multimonth rally to new highs — while the Standard and Poor’s 500 stock market index fell roughly 0.43%.

Crypto market sentiment is at a six-week lowCrypto market sentiment also appears to be worsening, with former Binance CEO Changpeng ‘CZ’ Zhao stating on Saturday that he is now “less confident” about the “Bitcoin supercycle” he predicted last month.

“Given all the FUD and all the emotions that were stirred up in the community, I’m less confident about it now,” he said during a Binance Square Ask Me Anything stream.

The Crypto Fear & Greed Index score fell six points to 14 out of 100 on Sunday, the lowest score in over a month.

Magazine: 6 weirdest devices people have used to mine Bitcoin and crypto

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Major banks are rapidly warming to digital asset payments and tokenization as strategic priorities, with senior directors signaling a clear shift from theoretical debate to real-world execution inside regulated financial systems.

Risk-off sentiment strengthened Sunday, triggered by a massive sell-off in leading cryptocurrencies and precious metals. Cryptocurrency 24-Hour Gains +/- Price (Recorded at 8:20 p.m.

Explore how two popular tech ETFs differ in diversification, holdings, and risk -- key factors for building a resilient portfolio.

The State Street Technology Select Sector SPDR ETF (XLK 2.04%) and the Fidelity MSCI Information Technology Index ETF (FTEC 1.75%) both target the U.S. technology sector, but they take slightly different approaches. XLK tracks a narrower slice of the S&P 500, while FTEC tracks a broader MSCI index covering more companies.

This comparison examines cost, performance, risk, portfolio composition, and other features to help investors determine which approach may appeal more.

Snapshot (cost & size)MetricXLKFTECIssuerSPDRFidelityExpense ratio0.08%0.08%1-yr return (as of Jan. 27, 2026)23.76%20.57%Dividend yield0.54%0.43%AUM$92 billion$17 billionBeta (5Y monthly)1.211.28Beta measures price volatility relative to the S&P 500. The 1-yr return represents total return over the trailing 12 months.

Both ETFs are equally affordable with a 0.08% expense ratio, but XLK offers a slightly higher dividend yield. The most notable difference in cost-related factors is scale: XLK’s assets under management (AUM) is more than five times larger than FTEC’s.

Performance & risk comparisonMetricXLKFTECMax drawdown (5 y)-33.56%-34.95%Growth of $1,000 over 5 years$2,129$2,210What's insideFTEC tracks the MSCI USA IMI Information Technology 25/50 Index, holding 289 stocks from various corners of the technology sector. Its top three positions — Nvidia, Microsoft, and Apple — make up more than 44% of assets, but the remaining holdings provide broader exposure across the sector.

XLK also targets technology, but with only 70 holdings. Its largest holdings match FTEC’s, but those three stocks make up just under 40% of the fund. Both ETFs carry no notable structural quirks and track major technology benchmarks.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsXLK and FTEC are similar in many ways, both focusing on the tech sector with heavy tilts toward industry-leading giants. The two funds have identical expense ratios, though XLK has a slight edge in income with a higher dividend yield.

While they have similar performance histories and risk profiles, FTEC has a slightly higher beta and a deeper max drawdown — suggesting marginally larger price swings over the last five years.

Diversification is one of the primary differences between them. FTEC is the broader of the two, with over four times as many holdings as XLK. However, it also has a slightly heavier tilt toward its top three holdings, with those stocks comprising 44% of the portfolio compared to 39% for XLK.

That may not seem like a major difference, but if Nvidia, Microsoft, or Apple performs particularly well or experiences significant volatility, it could widen the gap in total returns between these two funds.

The other major difference is AUM. XLK is substantially larger in this area, and greater liquidity allows investors to make larger transactions without causing the fund’s price to swing. This may not necessarily be a deciding factor for everyday investors, but it’s something to consider when many of these ETFs’ other attributes are so similar.

Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates.

Tanager Wealth Management disclosed in a January 26 filing that it sold out its entire Centessa Pharmaceuticals (CNTA 1.29%) stake in the fourth quarter, an estimated $14.50 million trade based on quarterly average pricing.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated January 26, Tanager Wealth Management LLP eliminated its full position in Centessa Pharmaceuticals, selling 598,044 shares. The estimated transaction value was $14.50 million based on the last-disclosed position value.

What else to knowTanager Wealth Management LLP’s exit means CNTA now represents 0% of reportable 13F AUM (down from 1.5% the prior quarter).

Top holdings after the filing:

NYSEMKT:ITOT: $148.38 million (14.8% of AUM)NYSEMKT:XHLF: $88.18 million (8.8% of AUM)NYSEMKT:VEA: $69.60 million (6.9% of AUM)NYSEMKT:PICB: $68.47 million (6.8% of AUM)NYSEMKT:VTI: $66.68 million (6.7% of AUM)As of January 26, CNTA shares were priced at $25.73, up about 56.7% over the past year and vastly outperforming the S&P 500’s roughly 14% gain in the same period.

Company overviewMetricValuePrice (as of 1/26/26)$25.73Market Capitalization$3.46 billionRevenue (TTM)$15.00 millionNet Income (TTM)($242.70 million)Company snapshotCentessa Pharmaceuticals develops a portfolio of clinical-stage and emerging pipeline products, including Lixivaptan for polycystic kidney disease and SerpinPC for hemophilia, as well as several early-stage candidates targeting autoimmune, respiratory, and rare diseases.The company operates a research-driven business model focused on the development of proprietary therapeutics in the biotechnology sector.Centessa focuses on developing therapies for patients with unmet medical needs in rare and serious disease segments.Centessa Pharmaceuticals plc is a clinical-stage biotechnology company headquartered in the United Kingdom, with a market capitalization of $3.46 billion and a focused pipeline in rare and serious diseases. The company leverages a diversified portfolio approach, advancing multiple candidates across nephrology, hematology, immunology, and respiratory indications. Its strategy centers on developing differentiated therapies for underserved patient populations, aiming to establish a competitive edge through innovation and clinical expertise.

What this transaction means for investorsAs you might expect from a wealth advisory, a large part of Tanager Wealth Management’s capital sits in broad market and factor ETFs, so individual biotech positions like this one tend to have a narrower job. They are there to work when momentum and fundamentals align, not to linger indefinitely through binary risk.

To be very clear, however, Centessa’s fundamentals are moving in the right direction. In its latest earnings release, the company reported $349 million in cash, equivalents, and investments, and $250 million from investors in November. Additionally, a CEO transition announced in December also formalized Centessa’s shift to a more focused orexin strategy.

The stock reflected that progress, rising nearly 57% over the past year. But context matters. This fund’s largest holdings are broad equity and bond ETFs designed to reduce idiosyncratic risk. Against that backdrop, a single clinical-stage biotech can quickly become oversized after a sharp rally.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Centessa Pharmaceuticals Plc, Vanguard FTSE Developed Markets ETF, and Vanguard Total Stock Market ETF. The Motley Fool has a disclosure policy.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beyond Meat To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Beyond Meat between February 27, 2025 and November 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 1, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beyond Meat, Inc. ("Beyond Meat" or the "Company") (NASDAQ: BYND) and reminds investors of the March 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the book value of certain of Beyond Meat's long-lived assets exceeded their fair value, making it highly likely that the Company would be required to record a material, non-cash impairment charge; (2) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the U.S. Securities and Exchange Commission ("SEC"); and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On November 3, 2025, during pre-market hours, Beyond Meat issued a press release announcing that it would delay reporting its financial results for Q3 2025, citing the need for additional time to complete its impairment review.

On this news, Beyond Meat's stock price fell $0.265 per share, or 16.01%, to close at $1.39 per share on November 3, 2025.

On November 10, 2025, during post-market hours, Beyond Meat issued a press release announcing its financial results for Q3 2025. Among other results, Beyond Meat reported that its loss from operations for the quarter was $112.3 million, which included "$77.4 million in non-cash impairment charges related to certain of the Company's long-lived assets." (Emphasis added.)

On this news, Beyond Meat's stock price fell $0.12 per share, or 8.96%, to close at $1.22 per share on November 11, 2025.

Then, on November 11, 2025, during post-market hours, Beyond Meat hosted a conference call with investors and analysts to discuss its financial results for Q3 2025. During the call, the Company's Chief Financial Officer and Treasurer Defendant Lubi Kutua disclosed, in relevant part, that "[t]he total impairment amount of $77.4 million was . . . allocated to PP&E, operating lease ROU assets and prepaid lease costs on our balance sheet."

On this news, Beyond Meat's stock price fell an additional $0.105 per share, or 8.61%, to close at $1.115 per share on November 12, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Beyond Meat's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Beyond Meat class action, go to www.faruqilaw.com/BYND or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282202

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us